These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 15793102)

  • 1. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.
    Micek ST; Lloyd AE; Ritchie DJ; Reichley RM; Fraser VJ; Kollef MH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1306-11. PubMed ID: 15793102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
    Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
    J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa.
    Osmon S; Ward S; Fraser VJ; Kollef MH
    Chest; 2004 Feb; 125(2):607-16. PubMed ID: 14769745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
    Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment.
    Schramm GE; Johnson JA; Doherty JA; Micek ST; Kollef MH
    Crit Care Med; 2006 Aug; 34(8):2069-74. PubMed ID: 16763516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
    Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
    BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inappropriate initial antimicrobial therapy as a risk factor for mortality in patients with community-onset Pseudomonas aeruginosa bacteraemia.
    Cheong HS; Kang CI; Wi YM; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    Eur J Clin Microbiol Infect Dis; 2008 Dec; 27(12):1219-25. PubMed ID: 18575908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudomonas aeruginosa bloodstream infections in children and adolescents: risk factors associated with carbapenem resistance and mortality.
    Rodríguez NEG; Aguilera-Alonso D; Escosa L; Gómez-Gil MR; Manzanares Á; Ascaso MG; Bermejo-Gómez A; Abad MJG; Ramos AM; Núñez AS; Orellana MÁ; Cercenado E; Lozano JS; Calvo C; Baquero-Artigao F;
    J Hosp Infect; 2024 Jul; 149():56-64. PubMed ID: 38735628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa bloodstream infections in children: a 9-year retrospective study.
    Pilmis B; Alby-Laurent F; Fasola ML; Seegers V; Guery R; Guet-Revillet H; Postaire M; Toubiana J; Bille E; Lortholary O; Zahar JR
    Eur J Pediatr; 2020 Aug; 179(8):1247-1254. PubMed ID: 32080759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
    Micek ST; Welch EC; Khan J; Pervez M; Doherty JA; Reichley RM; Kollef MH
    Antimicrob Agents Chemother; 2010 May; 54(5):1742-8. PubMed ID: 20160050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial and clinical characteristics of health care- and community-acquired bloodstream infections due to Pseudomonas aeruginosa.
    Hattemer A; Hauser A; Diaz M; Scheetz M; Shah N; Allen JP; Porhomayon J; El-Solh AA
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3969-75. PubMed ID: 23733476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
    Lee CC; Lee CH; Hong MY
    Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.